Navigation Links
China Botanic Appoints Jack Zhao as Independent Director
Date:1/24/2013

HARBIN, China, Jan. 24, 2013 /PRNewswire/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines ("TCM") in China, today announced the appointment of Mr. Jack Zhao as a member of the Company's Board of Directors. Mr. Zhao will serve as an independent director, the Chairman of the Board's Audit Committee, the Audit Committee Financial Expert, and as a member of the Company's Compensation and the Nomination Committees.

Mr. Zhao, 31, has served as the cash management manager at Dreyfus Commodities (BJ) Trading Co., Ltd. since May 2012. Before that, he was employed as a finance manager with Glencore China Ltd. and as a transactional banking manager with Standard Chartered Bank (China) Ltd. He graduated with a Master's Degree in Finance from the University of International Business and Economics Beijing in 2006 and he also received a Bachelor's Degree in Economic Information Management from the University of International Business and Economics Beijing in 2004. Mr. Zhao has also held the CFA (Chartered Financial Analyst) charterholder designation since September 2011.

"We look forward to working with Mr. Zhao to further improve our financial management and internal controls while implementing best practices as a public company. In addition, we believe that Mr. Zhao's joining the Board will enable us to regain compliance with Section 803(B)(2)(a)(iii) of the NYSE MKT LLC Company Guide, which requires that at least one member of the Audit Committee be financially sophisticated," commented Mr. Shaoming Li , Chairman and CEO of China Botanic.

ABOUT CHINA BOTANIC PHARMACEUTICAL INCChina Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.

Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:CCG Investor Relations:China Botanic Pharmaceutical Inc.

Mr. Mark Collinson, PartnerMs. Portia Tan, IR Contact

Phone: +1-310-954-1343 (Los Angeles)Tel: 86-451-8260-2162

Email: mark.collinson@ccgir.com Email: ir@renhuang.com

Website: www.ccgirasia.com


'/>"/>
SOURCE China Botanic Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. CentraState and Freehold Radiology Group train physicians from China
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
5. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
6. China Biologic Products Reports Higher Results for the First Quarter 2012
7. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
8. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
9. China Botanic Attends 67th PHARMCHINA Fair
10. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
11. China Botanic Attends the 111th China Import and Export Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D  printed ... as physics and manufacturing combine to progress molecular radiotherapy imaging. ... SPECT systems are unable to accurately quantify the radiation absorbed ... information regarding the success of this radiotherapy treatment has been ... ...
Breaking Medicine Technology:
(Date:7/24/2017)... Cambridge, MA (PRWEB) , ... July 24, 2017 , ... ... for an invigorating and educational conference, InstructureCon. Each annual event is coupled with a ... next level with a James Bond theme, Mission: InstructureCon 0017. , To extend ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the ... announces the issuance of United States Patent Number 9,695,398 (the '398 patent) and ... The '398 and '324 patents cover methods and systems for optimizing fat ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Paul Vitenas, ... the nation’s top level plastic surgeons, invited to attend Allergan’s recent meeting with their ... most valued companies in the world, Allergan is bringing a newly defined structure to ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... ... “Nana Nana Boo Boo”: a delightful tale of a young girl who ... Boo” is the creation of published author Michael Rush, a Deputy Sheriff, former world ... Rush’s new book presents the importance of manners in a way easily understood by ...
Breaking Medicine News(10 mins):